Prospective epidemiological studies have indicated that low Se concentrations in blood or deficiency in the circulating Se transporter selenoprotein P (SELENOP) predispose to an increased CRC risk [21,22], and shorter survival [23]. This evidence concerns the gene SELENOP and colorectal carcinoma.